New capture kit product will enable whole exome sequencing and targeted copy number analysis in a single assay
Birmingham, UK, 16 October 2019: Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data.
The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.
ExomeCG is a clinically enhanced exome capture kit which, for the first time, will enable the genomics community to perform confident and robust whole exome sequencing and targeted copy number analysis in a single assay. The clinically validated test replaces the need for chromosomal microarray and multiplex ligation-dependent probe amplification (MLPA) front line tests, saving time and cost while achieving the highest diagnostic yield possible.
ExomeCG is designed to provide unparalleled coverage of clinical targets when used in combination with the Congenica® clinical decision support platform, which enables fast and accurate interpretation of NGS data for healthcare professionals to deliver world-class genomic medicine services and make important clinical decisions. Under the agreement Nonacus will supply the Congenica® software platform alongside the Exome CG product and the wider Nonacus Cell3 Target™ product range, to provide an end-to-end solution for postnatal and prenatal analysis.
Chris Sale, Chief Executive Officer of Nonacus, said: “The launch of ExomeCG enables us to deliver a comprehensive clinical bioinformatics service to our customers and advance clinical cytogenomics by providing a robust, cost effective and user-friendly laboratory and analysis workflow.The current cytogenomics paradigm typically requires a multi-test strategy whereby chromosomal microarrays are first run achieving a modest 15% diagnostic yield. Subsequently, exome sequencing is undertaken in order to raise the diagnostic yield to around 40%. ExomeCG now offers a validated single test solution, enabling customers to obtain the highest diagnostic yield while removing additional workflows and the associated time and costs.”